2025: Volume 8, Issue 2
Rapid Communication P.1-2
Monoclonal Antibodies in COVID-19 Treatment: Efficacy and Limitations
Author(s):
Ane Sumbayev
DOI: 10.35841/aajcit-8.2.256
Perspective P.1-2
VT-Cell Exhaustion vs. Activation: Implications for Immunotherapy
Author(s):
Bein Lui
DOI: 10.35841/aajcit-8.2.257
Commentary P.1-2
The Role of Costimulatory Molecules in T-Cell Activation
Author(s):
Renee Jakobsen
DOI: 10.35841/aajcit-8.2.258
Commentary P.1-2
Checkpoint Inhibitors and T-Cell Activation: Enhancing Immune Response
Author(s):
Karin Asara
DOI: 10.35841/aajcit-8.2.259
Opinion Article P.1-2
How Monoclonal Antibodies Work: Mechanisms, Applications, and Future Prospects
Author(s):
Lingwen Xiang
DOI: 10.35841/aajcit-8.2.260
Opinion Article P.1-2
Harnessing T-Cell Activation for Vaccine Development
Author(s):
Emaad Duweb
DOI: 10.35841/aajcit-8.2.261
Perspective P.1-2
The Future of Monoclonal Antibodies: Innovations in Personalized Medicine
Author(s):
Wenjuan Jin
DOI: 10.35841/aajcit-8.2.262
Rapid Communication P.1-2
Exploring the Side Effects and Safety Concerns of Monoclonal Antibody Treatments
Author(s):
Filipo Milanese
DOI: 10.35841/aajcit-8.2.263
Short Communication P.1-2
T-Cell Activation in Autoimmune Diseases: A Double-Edged Sword
Author(s):
Yilong Han
DOI: 10.35841/aajcit-8.2.264
Short Communication P.1-2
The Role of Monoclonal Antibodies in Cancer Treatment: Advances and Challenges
Author(s):
Enric Macholi
DOI: 10.35841/aajcit-8.2.265